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Sonic hedgehog (Hh) signaling plays a key role in epidermal development and skin cancer. Mutational inactivation
of the tumor suppressor gene patched (PTCH) leads to constitutive activation of the Hh signaling pathway,
resulting in activation of target gene transcription by the zinc ﬁnger transcription factors GLI1 and GLI2. Recent
experiments in mice point to GLI2 as the key mediator of Hh signaling in skin. We have concentrated on the
identiﬁcation of candidate mediators of GLI2 function in the human epidermis. We show here that the forkhead/
winged-helix domain transcription factor FOXE1 is likely to be a direct GLI2 target gene. The kinetics of FOXE1
induction are similar to the known direct target PTCH, and a 2.5 kb upstream fragment containing ﬁve GLI-binding
sites activates transcription in a reporter assay. We show by in situ hybridization that FOXE1 is expressed in the
outer root sheath of the hair follicle, where murine Gli2 is also expressed. FOXE1 expression is also found in basal
keratinocytes of the human epidermis and basal cell carcinoma (BCC). These data point to a putative role of FOXE1
in mediating Hh signaling in the human epidermis downstream of GLI2.
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Hedgehog (Hh) signaling plays a key role in vertebrate
development, where it is involved in a multitude of biological
processes such as cell differentiation, proliferation, and
growth (reviewed in Ingham and McMahon, 2001; Nybak-
ken and Perrimon, 2002). Inappropriate activation of Hh
signaling has been implicated in developmental defects and
a predisposition to various malignancies such as basal cell
carcinoma (BCC), medulloblastoma, and rhabdomyosarco-
ma (reviewed in Toftgard, 2000; Bale, 2002; Mullor et al,
2002). Analysis of hereditary and sporadic BCCs revealed
that ligand-independent activation of Hh signaling in
epidermal cells is the primary event in tumorigenesis.
Uncontrolled activation is caused by inactivating mutations
in the human tumor suppressor gene patched (PTCH) or, in
rare cases, by gain-of-function mutations in the Smooth-
ened gene (SMOH) (Gailani et al, 1996; Hahn et al, 1996;
Johnson et al, 1996; Aszterbaum et al, 1998; Xie et al, 1998).
Normally, transduction of the HH signal is triggered by
binding of secreted HH protein to the 12 pass transmem-
brane receptor protein (PTCH). Binding of HH to PTCH is
thought to relieve the inhibitory effect of PTCH on the seven
pass transmembrane protein Smoothened (SMOH), leading
to transduction of the signal to the nucleus (reviewed in
(Ingham and McMahon, 2001; Nybakken and Perrimon,
2002). The zinc finger transcription factors (TF) GLI1 and
GLI2 have been identified as key mediators of HH signal
transduction and like PTCH are themselves HH target genes.
Consequently, BCCs express elevated levels of GLI1, GLI2,
and PTCH, and other HH target genes (Gailani et al, 1996;
Dahmane et al, 1997; Ghali et al, 1999; Regl et al, 2002).
Support for a critical role of GLI1 and GLI2 in BCC
development has come from transgenic mouse models
showing that overexpression of either protein in epidermal
cells can induce the formation of tumors, some of which
display BCC-like characteristics (Grachtchouk et al, 2000;
Nilsson et al, 2000; Sheng et al, 2002). More recently,
studies of knockout mice have pointed to a role of Gli2
rather than Gli1 as the primary mediator in Hh signal
transduction. Firstly, mice deficient in Gli1 are viable and
have no obvious developmental defects (Park et al, 2000). In
contrast, Gli2/ mice are characterized by severe devel-
opmental malformations, including the lack of the floor plate
of the neural tube and of the anterior pituitary, and by
numerous lung, foregut, skeleton, and skin defects (Ding
et al, 1998; Matise et al, 1998; Mill et al, 2003). This Gli2
phenotype broadly overlaps with that described for Shh- or
Ihh- deficient mice (Chiang et al, 1996, 1999; St-Jacques
et al, 1999). Secondly, removal of Gli2 but not of Gli1 leads
to partial rescue of the ptc/ phenotype, where Hh sig-
naling is hyperactivated (Bai et al, 2002). Thirdly, Gli2 but not
Gli1 is required for Hh signaling in hair follicle development
(Mill et al, 2003). Together, these findings suggest that Gli2
rather than Gli1 is the primary transducer of the Hh signal.
To elucidate the mechanism by which GLI2 controls
HH-mediated epidermal development and skin cancer, we
Abbreviations: BCC, basal cell carcinoma; Hh, hedgehog; PTCH,
12 pass transmembrane receptor protein; PTCH, human tumor
suppressor gene patched; Tet, tetracycline
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focused on the identification of GLI2-regulated genes with a
putative role in mediating Hh signaling downstream of GLI2
in epidermal cells. Here, we present data that the forkhead
transcription factor FOXE1 may be a direct GLI2 target
gene. Like GLI2, FOXE1 is expressed in normal epidermis
and BCC, suggesting an involvement of FOXE1 in executing
the transcriptional program triggered by GLI2.
Results
Overexpression of GLI2 in human keratinocytes in-
creases FOXE1 mRNA levels To identify GLI2-regulated
genes, we have expressed GLI2 in human keratinocytes
followed by cDNA array analysis of GLI2 expressing cells
and controls. We have genetically modified the human
keratinocyte cell line HaCaT (Boukamp et al, 1988) to allow
tetracycline (tet)-inducible expression of human GLI2
(referred to as HaCaT-GLI2His) (Regl et al, 2002). Tet-
inducible cell lines offer the advantage of precise temporal
control of GLI2 expression, which has proved invaluable for
the identification of early target genes. Expression profiling
of samples treated with tet for 24 and 72 h, respectively,
was carried out on filter arrays containing approximately
2200 human expressed sequence tag (EST) (unpublished
data). To eliminate differences between clonal HaCaT-
GLI2His lines, RNA from four independently isolated lines
was pooled and used for cDNA array analysis. As shown in
Fig 1, the forkhead transcription factor FOXE1 was highly
upregulated in a GLI2 concentration-dependent manner
compared with controls, with a (5.4  0.94)-fold increase after
24 h and a (10  1.15)-fold increase after 72 h of tet treatment.
Since cell lines derived from the spontaneously immor-
talized HaCat cell line may not always reflect the situation in
primary cells, the induction of FOXE1 in response to GLI2
was confirmed in primary human keratinocytes infected
with either GLI2 expressing retrovirus (SIN-GLI2-EGFP) or
retrovirus expressing EGFP (SIN-EGFP) only as reference
(Regl et al, 2004). Expression of FOXE1 and the direct target
PTCH as control was measured by real-time RT-PCR in cells
72 h after infection. Similar to HaCaT-GLI2His cell lines, a
strong induction of FOXE1 transcription ((16.6  0.3)-fold)
and PTCH ((19.78  2.45)-fold) was detected in retrovirally
infected primary keratinocytes expressing GLI2 (data not
shown).
Real-time RT-PCR was also used to validate FOXE1
induction levels as measured by cDNA arrays in HaCaT cell
lines expressing GLI2. Additionally, the kinetics of the
transcriptional response of FOXE1 and the appearance of
the GLI2 protein were simultaneously analyzed in detail
(Fig 2A, B). RNA and protein samples were taken from
HaCaT-GLI2His cells induced for 6 h, 12, 24, and 48 h with
tet and compared with untreated controls from the same
time points. GLI2 protein was clearly increased over
background expression level, also seen in uninduced cells
6 h after tet addition, and levels further increased with
prolonged treatment (Fig 2A). Similarly, FOXE1 transcript
levels were already elevated (3.42  0.25)-fold at 6 h of tet
treatment and further increased in a GLI2 concentration-
dependent manner ((7.17  1.39)-fold at 12 h, (20.61 
0.57)-fold at 24 h up to (36.9  1.02)-fold at 48 h). The
kinetics of FOXE1 mRNA accumulation were compared
with those of the known GLI target PTCH and a similar
Figure 1
FOXE1 is upregulated in response to GLI2 expression in HaCaTand
primary human keratinocytes. cDNA array screen for GLI2 target
genes in HaCaT-GLI2His cell lines. The upregulation of FOXE1
transcript is shown as fold induction compared with uninduced
samples. Tetracycline was added at the times indicated. Average
induction and standard deviation (SD) were calculated from eight data
points. Spots representing FOXE1 are shown in the upper panel (black
arrowheads).
Figure2
FOXE1mRNA expression is an early response to GLI2. Time-course
analysis of FOXE1 expression in HaCaT-GLI2His cells treated with
tetracycline for the times indicated is shown. (A) Western blot of
GLI2His transgene expression. (B) Real-time RT-PCR measurements of
FOXE1 mRNA levels. For comparison, patched (PTCH) is shown.
Expression levels are given as fold induction compared with uninduced
samples. Data represent the average of three independent PCR runs
carried out in duplicate. Error bars are given as standard deviation (SD).
All results were normalized for total RNA amount using large ribosomal
protein P0 (RPLP0) as reference (Martin et al, 2001).
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response was observed ((7.82  0.17)-fold at 6 h, (8.15 
0.24) at 12 h, (23.57  1.1) at 24 h and (26.63  2.3)) (Fig
2B). The rapid increase in FOXE1 mRNA transcription in
response to GLI2, which was also observed by northern blot
(data not shown), suggests that FOXE1 represents an early
GLI2 target gene, which like PTCH may be directly
regulated by GLI2.
Since GLI1 and GLI2 recognize the same consensus-
binding sequence and are known to have overlapping func-
tions (Bai and Joyner, 2001), we compared the induction of
FOXE1 by GLI1 and GLI2 in the respective HaCaT cell lines.
Expression levels for FOXE1 and PTCH, given as fold
induction compared with uninduced samples, are shown in
Table I.
In contrast to the strong induction of FOXE1 mRNA
levels in response to GLI2, a significantly reduced activation
of FOXE1 was detected in HaCaT cells expressing GLI1,
pointing to GLI2 as the main activator. No such differences
were observed for PTCH, which was upregulated to com-
parable mRNA levels in HaCaT-GLI1 as well as in HaCaT-
GLI2His cell lines. Since, however, there exists a positive
feedback loop between GLI1 and GLI2 expression (Regl
et al, 2002), it is difficult to say what part of FOXE1
activation by GLI1 may actually be due to GLI2.
The promoter region of FOXE1 contains GLI-binding
sites The early response of FOXE1 to GLI2 prompted us to
investigate whether FOXE1 might be directly regulated by
GLI2. We analyzed the putative FOXE1 promoter region
encompassing from 2000 to þ 688 (translational start site)
relative to the transcriptional start site (þ 1) for the presence
of potential Gli-binding sites. Since the transcription start for
FOXE1 was not exactly known, we mapped it by 50-RACE
to a position 28 bp upstream of the known mRNA 50 end
(Acc. no.: NM_004473) (data not shown).
Five sites differing from the GLI-binding consensus motif
GACCACCCA (Kinzler and Vogelstein, 1990) by two
nucleotide substitutions were found (Fig 3A, B). All were
shown to interact specifically with recombinant purified
GLI2 Zn protein (amino acids 1–332, truncated after the Zn
finger DNA-binding domain) in electrophoretic mobility shift
assays (EMSA) (data not shown).
In a luciferase reporter gene assay, a 2470 bp fragment
(1934 toþ536) (Fig 3A) containing all five GLI-binding
sites was shown to activate transcription 3-fold in the
presence of GLI2 compared with control (Fig 3C). The early
response of FOXE1 transcription to GLI2, and the presence
of GLI-binding sites in the FOXE1 promoter region, together
with the activation of the FOXE1 promoter in a reporter
assay, indicate that FOXE1 is a likely direct target of the
GLI2 transcription factor in epidermal cells.
FOXE1 is overexpressed in BCCs We have previously
shown that GLI2 mRNA levels are highly elevated in BCC
samples compared with normal skin (Regl et al, 2002). Thus,
if FOXE1 acts as a downstream target of GLI2 in vivo and
has a relevant role in GLI2 induced processes such as BCC
development, FOXE1 should also be present in these
tumors. We have, therefore, analyzed BCC samples with
known GLI2 and GLI1 levels (Regl et al, 2002) for FOXE1
transcript levels (Table II). In all 15 BCC samples tested,
FOXE1 mRNA was detected at levels higher than in normal
skin. The normal skin sample, used as standard in all
experiments, consisted of a pool of four independently
isolated human skin biopsies to reduce site-specific and
Table I. FOXE1 transcription is preferentially activated by GLI2
þTet (h)
FOXE1 mRNA (  SD) PTCH mRNA (  SD)
12 24 72 12 24 72
HaCaT-GLI1 2.15 5.83 11.97 8.67 13.27 20.96
(  0.09) (  0.19) (  2.40) (  1.05) (  0.28) (  1.12)
HaCaT-GLI2His 6.16 19.65 39.60 13.48 13.95 24.57
(  0.52) (  1.90) (  5.19) (  1.14) (  1.99) (  5.81)
Tet, tetracyline; HaCaT-GLI2His, tet-inducible expression of human GLI2.
Figure3
The 50 upstream region of FOXE1 contains potential GLI binding
sites. (A) Location of five GLIi-binding sites (1–5), which were identified
by EMSA analyses. (B) Sequence and position of the binding sites
relative to the transcriptional start site (þ1) as determined by 50RACE.
Bases that differ from the published GLI binding consensus sequence
(GACCACCCA (Kinzler and Vogelstein, 1990)) are underlined. C)
Luciferase reporter assay showing activation of the putative FOXE1
promoter (1934 to þ536) by GLI2. HaCaT cells were transfected with
FOXE1 promoter reporter construct (FOXE1prom), together with either
control vector or GLI2 expression vector. Data represent average value
of three independent experiments. RLU, relative luciferase units.
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individual variations. It should be noted that GLI2 and
FOXE1 are expressed at a much higher level in normal skin
than GLI1. These ratios shown do not reflect absolute
concentration. Upregulation of FOXE1 mRNA levels ranged
from 4-fold (BCC9) to 59.2-fold (BCC25) with an average
fold increase of 15.8-fold. Pearson’s correlation was
calculated pairwise for GLI1 versus FOXE1, GLI2 versus
FOXE1 and GLI1 versus GLI2 using SPSS (SPSS, Chicago,
IL). Only FOXE1 versus GLI2 showed significant correlation
(po0.01) (Table II). Since upregulation of FOXE1 expression is
GLI2 dependent in a cultured human keratinocyte line as well
as in primary human keratinocytes, it is likely that the elevated
levels of FOXE1 reflect increased GLI2 activity in BCC.
In situ localization of FOXE1 in BCC and normal
skin We next investigated FOXE1 expression in BCC by
in situ hybridization. In agreement with the results of real-
time RT-PCR, all tested BCC (n¼6) showed intense staining
throughout the tumor islands (Fig 4A, C). No specific signal
was detected in the surrounding stroma cells. The speci-
ficity of tumor staining was demonstrated by hybridizing
adjacent sections with FOXE1 sense RNA probes (Fig 4B,
D). Thus, the results show that the elevated FOXE1
transcript level detected with real-time RT-PCR in BCC is
specific for the epithelial component of the BCC samples
and does not result from expression in surrounding
mesenchymal tissues.
Next, we analyzed follicular and interfollicular human
epidermis for FOXE1 mRNA expression. In interfollicular
epidermis, specific staining was detected in the basal
and suprabasal layers but not in the underlying mesoderm
(Fig 5A, C). It should be pointed out that the quantitative RT-
PCR data in Table II indicate that expression must be much
lower than in BCC. In hair follicles, the highest level of
FOXE1 mRNA was present in the outer root sheath (Fig 5C,
E). Occasionally, staining of mesenchymal cells of the
perifollicular connective tissue sheath was observed.
Discussion
HH/GLI signaling has been implicated in the regulation of
hair follicle development and skin tumorigenesis (Iseki et al,
1996; Oro et al, 1997; St-Jacques et al, 1998; Chiang et al,
1999; Oro and Higgins, 2003). A growing body of data
points to a decisive role of the zinc finger transcription
factor GLI2 in mediating these processes in response to HH
signaling (Bai et al, 2002; Sheng et al, 2002; Mill et al, 2003).
In a search for potential downstream mediators of GLI2
function in epidermal cells, we have identified a new GLI2
target gene, FOXE1, whose expression is strongly en-
hanced in response to GLI2. The presence of five GLI-
binding sites in the putative promoter region of FOXE1,
together with the activation of reporter gene expression by
this region in the presence of GLI2, points to direct
regulation of FOXE1 by GLI2. The largely overlapping
expression domains of FOXE1 and GLI2 in human hair
follicles, epidermis, and BCC Ikram et al,1 suggest a role of
Table II. Comparison of FOXE1, GLI2, and GLI1 mRNA levels in BCCa
BCC ID FOXE1 (  SD)b GLI2c GLI1c Type Origin
25 59.21 (  1.03) 67.28 1861.82 Nodular Neck
37 32.41 (  6.00) 16.14 53.02 Nodular Back
6 25.66 (  4.58) 5.63 16.51 Nodular Head
32 22.78 (  2.28) 18.22 591.81 Nodular Pool of 3
38 22.59 (  0.55) 18.61 128.80 Nodular Upper arm
27 15.54 (  1.82) 8.62 225.03 Nodular Head
12 12.37 (  1.49) 8.02 267.43 Nodular Head
23 10.72 (  2.36) 13.70 814.63 Nodular Head
31 10.11 (  2.12) 5.65 135.96 Nodular Back
30 8.73 (  0.66) 12.32 206.64 Nodular Thorax
18 7.32 (  0.42) 7.89 3024.54 Nodular Head
2 7.29 (  0.27) 9.74 116.48 Nodular Head
35 5.58 (  0.19) 2.81 17.82 Nodular Thorax
8 4.84 (  0.72) 6.69 95.50 Nodular Thorax
9 4.02 (  0.28) 3.35 157.53 Nodular Head
aThe Pearson correlation (two-tailed) was calculated pairwise using SPSS for all combinations. Only FOXE1 versus GLI2 was significant at 0.01 level
with a Pearson coefficient of 0.883.
bValues for FOXE1 expression represent the ratio of FOXE1 mRNA in tumor to that in normal skin. Ratios and SD were calculated from the average of
four real-time RT-PCR measurements.
cData for GLI2 and GLI1 expression are taken from Regl et al (2002) and are shown here for comparison. The same tumor samples were used for
FOXE1 mRNA.
BCC, basal cell carcinoma.
1Ikram SI, Neill GW, Regl G, et al: GLI2 is expressed in normal
human epidermis and BCC and induces GLI1 expression by
binding to its promoter. Accepted for publication, J Invest Dermatol
(MS JID-2003-0435)
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FOXE1 in epidermal development and carcinogenesis
downstream of HH/GLI signaling. Whether expression of
FOXE1 in interfollicular epidermis is dependent on HH
signaling is unclear since expression of well-characterized
Hh targets such as GLI1 and PTCH is mainly restricted to
follicular regions of the skin. Co-expression of FOXE1 and
GLI2 in interfollicular epidermis may therefore be controlled
by signals other than Hh, a situation that has been
described for Gli2 in ventroposterior mesoderm formation
of Xenopus, where Gli2 expression is induced by FGF rather
than Hh signaling (Brewster et al, 2000).
FOXE1 (also named FKHL15/TTF2) belongs to a large
family of transcription factors characterized by their DNA-
binding domain—the forkhead/winged-helix motif. In vitro
analysis of the mechanism of foxe1 action suggested a role
for Foxe1 as a transcriptional repressor (Zannini et al, 1997;
Perrone et al, 2000). Forkhead proteins display a remark-
able functional diversity and are implicated in a variety of
biological processes ranging from embryonic development
to regulation of cell growth and proliferation in adult tissues
(Kaufmann and Knochel, 1996; Carlsson and Mahlapuu,
2002). Notably, expression of several mammalian forkhead
genes has been shown to be controlled by the Hh/Gli
signaling pathway: foxa2 (HNF-3b), expressed in the floor
plate of the notochord via direct transcriptional regulation
by GLI1 (Sasaki et al, 1997), foxc2 (Mfh1) and foxd2
(FREAC-9/Mf2) (Wu et al, 1998; Furumoto et al, 1999), both
involved in sclerotome cell proliferation, foxf1 (FREAC-1/
HFH-8) in lung and foregut mesenchyme (Mahlapuu et al,
2001), and FOXM1 (Trident/HFH-11/INS1) in human BCC
(Teh et al, 2002).
Although FOXE1 was originally isolated from keratino-
cytes (Chadwick et al, 1997), its role in epidermal develop-
ment and homeostasis is not understood. FOXE1/TTF2
function has primarily been investigated in the context of
thyroid development (Zannini et al, 1997; Clifton-Bligh et al,
1998; De Felice et al, 1998; Damante et al, 2001; Castanet
et al, 2002). Mice lacking both copies of foxe1 suffer from
neonatal hypothyroidism characterized by a sublingual
small ectopic or completely missing thyroid gland and
cleft palate (De Felice et al, 1998). Patients with Bamforth
syndrome, who are heterozygous for FOXE1, display in
addition to thyroid agenesis a spiky hair phenotype (Clifton-
Bligh et al, 1998; Castanet et al, 2002). A corresponding hair
phenotype was not observed in foxe1/ mice since they
die before hair formation (De Felice et al, 1998). Expression
of foxe1 was, however, observed in embryonic whiskers of
wild-type mice (Dathan et al, 2002). Together with the spiky
hair phenotype of Bamforth patients, this points to a role of
Foxe1 in hair follicle development where Gli2 is essential
(Mill et al, 2003).
In summary, we have characterized FOXE1 as a novel
GLI2 target gene in human keratinocytes. Given the critical
role of GLI2 in the proliferation of hair follicle cells and
tumorigenesis, co-expression of FOXE1 and GLI2 in normal
skin and BCC suggests that FOXE1 may be involved in
mediating the proliferative effect of GLI2 in vivo. Functional
analysis of FOXE1 in epidermal development and disease
will thus be a major aim of future studies to shed new light
on the molecular mechanisms downstream of the Hh/GLI
signaling pathway.
Materials and Methods
RNA isolation and real-time RT-PCR analyses BCC and normal
skin were snap-frozen after surgical removal and stored at 701C
until use. Ethical committee permission was obtained from the East
London and City Area Health Authority and all biopsies and skin
samples were taken with full patient consent. Total RNA was
isolated after homogenization with a high-speed dispersing tool
Figure 4
FOXE1mRNA localizes to BCC tumor islands.
FOXE1 expression is shown in two representa-
tive tumors by in situ hybridization. (A and C)
Only BCC tumor islands but not surrounding
stroma cells are stained. (B and D) Adjacent
sections were hybridized with sense RNA as
negative controls to show the specificity of
hybridization.
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(ULTRA TURRAX T18 basic, IKA Labortechnik, Staufen, Germany)
using TRI-reagent (Molecular Research Center, Cincinnati, Ohio)
followed by further purification using the High Pure RNA Isolation
Kit (Roche, Basel, Switzerland), which includes a DNAase treat-
ment to remove genomic DNA. RNA quality and quantity were
assayed on a Bioanalyzer 2100 (Agilent Technologies, Palo Alto,
California). cDNA was synthesized with Superscript II (Rnase H-)
reverse transcriptase (Invitrogen, Carlsbad, California) according to
the manufacturer’s instructions. Real-time RT-PCR analysis was
carried out on a Rotorgene 2000 (Corbett Research, Sydney,
Australia) using iQ SYBR Green Supermix (BIORAD, Hercules,
California). Fold-induction values (x) were calculated using the
following formula: x ¼ 2DDCt , where Ct represents the mean
threshold cycle of all replicate analyses of a given gene and DCt
represents the difference between the Ct values of the gene in
question (target) and the Ct value of the reference gene (RPLP0)
(Martin et al, 2001). DDCt is the difference between DCt values of
the samples for each target (e.g. DCt for FOXE1 in tumor) and the
mean DCt of the calibrator (e.g. DCt for FOXE1 in normal skin).
Primer sequences for real-time RT-PCR studies were as follows:
RPLPO forward primer (50–30) GGCACCATTGAAATCCTGAGT-
GATGTG, reverse primer (50–30) TTGCGGACACCCTCCAGGAAGC;
GLI2 forward primer (50–30) TGGCCGCTTCAGATGACAGATGTTG,
reverse primer (50–30) CGTTAGCCGAATGTCAGCCGTGAAG; PTCH
forward primer (50–30) TCCTCGTGTGCGCTGTCTTCCTTC, reverse
primer (50–30) CGTCAGAAAGGCCAAAGCAACGTGA; FOXE1 for-
ward primer (50–30) CATCTTGGATGCTGCCCTGCGTATT, reverse
primer (50–30) CCAGCACGTCCTGCTCAAAAGTTCA.
Screening of cDNA arrays A non-redundant set of 2200
sequence verified EST-clones obtained from the human-UniGem
V2.0 clone set (Incyte Genomics, Cambridge, UK) was amplified by
PCR and products were spotted in quadruplicate on a 22  11cm
nylon membrane (Hybond Nþ , Amersham Bioscience, Uppsala,
Sweden) using the MicroGridII arrayer (BioROBOTICS, Huntingdon,
UK). The membranes were hybridized with probes obtained from
total RNA prepared from GLI2 expressing HaCaT cells and controls
using TRI-reagent (Molecular Research Center, Cincinnati, Ohio)
followed by a LiCl precipitation step. Fifteen micrograms total RNA
from each sample were reverse transcribed with Superscript II
(Rnase H-) reverse transcriptase (Invitrogen) in the presence of 70
mCi [33P]dCTP (specific activity 3000 Ci per mmol) (Amersham
Bioscience). Labeled cDNA was purified with GFX DNA Purification
Kit (Amersham Bioscience). Hybridization was carried out for 36 h
in 5  SSC, 5  Denhard’s, 1% SDS followed by extensive
washing with 2  SSC, 0.1% SDS; 0.2  SSC, 0.1% SDS and
0.1% SSC, 0.1% SDS. Filters were exposed for 4 d onto a
phosphoimager screen (Fuji, Japan) and scanned with BAS-1800II
(Fuji, Tokyo, Japan). The images were analyzed using the AIDA
Metrix suite (RAYTEST, Straubenhardt, Germany).
Western blot analysis Western blot analysis of GLI2 protein
expression in HaCaT-GLI2His cells was performed according to
standard procedures using a monoclonal mouse anti-HIS perox-
idase-conjugated antibody (A7058, SIGMA-Aldrich, Vienna, Aus-
tria) followed by ECL detection (Amersham Bioscience). Proteins
were blotted on Hybond-ECL (Amersham Bioscience) and ex-
posed to Hyperfilm ECL (Amersham Bioscience).
Cell culture and generation of tet-inducible HaCaT lines HaCaT
cells were cultured in Dulbecco’s modified Eagle medium (DMEM
pH 7.2, high glucose, Invitrogen Life Technologies, Carlsbad,
California) supplemented with 10% fetal calf serum (FCS) (Invitro-
gen), 100 mg per liter streptomycin and 62.5 mg per liter penicillin
at 371C, 5% CO2 atmosphere. The T-Rex system (Invitrogen) was
used to generate double stable inducible HaCaT lines expressing
human GLI1 and GLI2 tagged with a 6  HIS epitope under the
control of the bacterial tet repressor (HaCaT-GLI2His). Double
stable lines were established and grown in the presence of Zeocin
(Invitrogen) and Blasticidin-S (ICN-Biomedica, Costa Mesa, Cali-
fornia). Transgene expression was induced by adding 1mg per liter
tet to the cell culture medium.
To generate the retroviral bicistronic GLI2-EGFP expression
construct, N-terminally His-tagged GLI2 was cloned into pI2E-A, a
modified version of pIRES2-EGFP plasmid (Clontech, Hampshire,
UK) (Regl et al, 2002). PI2E-A-GLI2 was digested with SalI and NotI
to excise CMV-GLI2-IRES-EGFP. The resulting fragment was
cloned into XhoI- and NotI-digested retroviral SIN-IP plasmid (a
gift from Prof. P. Khavari) to create SIN-GLI2-EGFP. Retrovirus
production and transduction of primary keratinocytes were carried
out as previously described (Regl et al, 2002).
Luciferase reporter assay The 50 upstream regulatory region of
the human FOXE1 gene from 1934 to þ 539 relative to the
transcriptional start site was amplified by PCR from genomic DNA
Figure 5
FOXE1 is expressed in the human epidermis and the outer root
sheath of the hair. FOXE1 mRNA expression was visualized by in situ
hybridization (A and C) Specific staining for FOXE1 was observed in
basal keratinocytes of a normal human epidermis (red arrows). E)
Sections of a hair follicle show that FOXE1 transcript is strongly
expressed in cells of the outer root sheaths of the hair. (B, D, and F)
Adjacent sections were hybridized with a sense RNA probe (control) to
demonstrate the specificity of the hybridization.
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using FailSafe PCR system (Epicentre, Madison, WI). The following
primers were used: Forward primer: 50-GAATTAAGGAAGGAGA-
GAACTGCGG-30, reversed primer 50-GAGAAGCTTCCGCGTGG-
TGCTTCTCGAGGCGGGC-30. PCR fragment was digested with
HindIII and cloned into the HindIII site of pGL3basic reporter vector
(Promega, Madison, Wisconsin) yielding the construct FOXE1-
prom. For luciferase reporter assays, HaCaT cells were co-
transfected in 12-well plates with FOXE1 (FOXE1prom) reporter
plasmid and GLI2 expression plasmid (human full-length GLI2b
(Acc. no. AB007296.1) (a gift from Dr David Markovitz) in pcDNA4/
TO (Invitrogen)) or empty pcDNA4/TO. b-Galactosidase expression
vector (pcDNA4/TO-LacZ; Invitrogen) was also co-transfected for
normalization of transfection efficiency. Cells were harvested 48 h
post-transfection and luciferase assays were carried out using
Luciferase Substrate (Promega), according to the manufacturer’s
instructions. Luciferase activity was measured on a Lucy II
luminometer (Anthos, Wals, Austria). To normalize results for lacZ
activity, 20 mL of cell lysate was mixed with 240 mL Z-buffer (100
mM NaPO4 (pH 7), 10 mM KCl2, 1 mM MgSO4, 50 mM b-
mercaptoethanol) and 50 mL O-nitro-a-D-phenyl-galactopyranoside
(ONPG, SIGMA-Aldrich)(4 mg per mL in 100 mM NaPO4) and
incubated at 281C until yellow color became visible. Reactions
were stopped by adding 250 mL 1 M Na2CO3. b-Galactosidase
activity was quantified by measuring absorbance at 405 nm on an
SLT-Spectra plate reader (SLT (Tecan), Groedig, Austria).
In situ hybridization DIG-labeled FOXE1 sense and antisense
probes were generated from a 332 bp BamHI/PstI fragment of the
30 UTR of FOXE1 (corresponding to nucleotides 2148–2480,
GenBank GI No. 2078532) subcloned into pBluescript II KS, using
a DIG labeling kit (Roche) as described by the manufacturer’s
instructions. 8 mm tissue sections were pre-hybridized in pre-hyb-
solution (4  SSC, 1  Denhardt’s, 50% formamide, 500 mg per
mL tRNA and 500 mg per mL salmon testes DNA (denatured at
1001C for 10 min and placed on ice before adding to the mix) and
incubated at 421C for 3–4 h. Hybridization was carried out using
fresh pre-hyb-solution containing 80–100 ng labeled probe
(denatured at 651C for 5 min) at 421C overnight. Next day, the
sections were washed in 2  SSC for 5 min (two times) and in 2 
SSC, 1  SSC, 0.5  SSC, each containing 50% formamide, at
451C–551C and in 0.1  SSC 50% formamide at 501C –601C for
20 min. A final wash in 2  SSC and rinsed in DIG buffer 1 (100
mM Tris-HCl, 150 mM NaCl pH 7.5). Sections were blocked with
10% normal sheep serum (NSS) in DIG buffer 1 and incubated with
anti-digoxigenin-alkaline phosphatase-conjugated (Roche) diluted
1:400 in 1% NSS DIG buffer 1 for 2 h, followed by washing in DIG
buffer 1 (  2) and DIG buffer 2 (100 mM Tris-HCl pH 9.5, 100 mM
NaCl, 50 mM MgCl2) for 10 min. The hybrids were visualized
by incubating the section with BCIP/NBT (SIGMA-Aldrich) liquid
substrate in dark at 41C overnight. The color reaction was stopped
by immersing the sections in (10 mM Tris-HCl pH 8, 1 mM EDTA)
for 30 min. The developed slides were mounted and examined
under a light microscope.
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